Light Anti-Aging Line — Premium Documentation at a First-Line Price

The problem this playbook solves: first anti-aging products fight on adjectives — the 30–40 buyer wants a documented ingredient story at an accessible tier, and the shelf does not offer one.

01 · The problem

The 30–40 first-anti-aging buyer has read ingredient lists for years. The shelf answers with adjective wars — peptide names, percentage theatre, clinical imagery — while the actual differentiator, a documented material chain, is reserved for premium tiers. An accessible-tier line with an ingredient story that survives diligence — that product is not on the shelf yet.

02 · Scientific rationale

The credible core is exosomal material with a documented chain: DMF Type II on the material line, INCI registration, national-standard drafting participation, and batch COAs — plus published early human signal for topical EV application (hydration, elasticity, overall appearance in a 2026 systematic review of 19 studies) [3]. Claims stay at appearance level; the documentation does the premium work.

03 · Program documentation

Protocol documentation for this program family is maintained in TONGNIAN's internal files — network-clinic protocol series and anonymized case records where applicable [5]. Partner access under NDA; the evidence hierarchy stays explicit — published reviews first, internal observational programs second, case documentation third. [6]

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line — closed-tubing culture, scheduled harvest, tangential-flow separation and concentration, sterile filtration — with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17, TONGNIAN a drafting organization) [3].

Fig. 1 — The four-format family on one baseline.

06 · Regulatory pathway: EU & US first

EU cosmetic track (CPNP, PIF/CPSR, Reg. 655/2013 claims criteria) and US MoCRA — appearance-level wording only. Material chain: DMF Type II 044197, INCI 41316, national-standard drafting. China CSAR later — additional market.

07 · Expected outcomes

• Accessible tier, premium documentation: a diligence-proof story at first-line pricing.
• Family economics: four formats, one baseline — line extension without re-development.
• Appearance-level claims that survive EU 655/2013 and US advertising review.

Wording stays inside each destination market's rules; batch measurement does the persuading.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label and program naming run through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Systematic review of 19 human studies of topical exosome skin applications, 2026 — summary via DermatologyNews.net.
3. Théry C, et al. MISEV2018: minimal information for studies of extracellular vesicles. J Extracell Vesicles. 2018;7(1):1535750.
4. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17), national standard — TONGNIAN, drafting organization.
5. TONGNIAN network clinics. Anonymized internal protocol and case documentation (partner access under NDA).